The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.
# Materials

| Antibodies | Yes (indicate where provided: section/paragraph) | n/a |
|------------|-------------------------------------------------|-----|
| For commercial reagents, provide supplier name, catalogue number and RRID, if available. | Anti-N-cadherin, anti-LRIG, anti-E-cadherin, and anti-Vimentin (CST, USA, 13116(RRID:AB_2687616), 12752 (RRID:AB_2798016), 14472(RRID:AB_2728770), and 3390(RRID:AB_2216128)) Anti-SLUG, anti-Snail, and secondary antibodies(Abcam, ab106077(RRID:AB_11159263), ab216347, and ab96899(RRID:AB_10679361)) | |

| Cell materials | Yes (indicate where provided: section/paragraph) | n/a |
|----------------|-------------------------------------------------|-----|
| Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | hFOB1.19, and human OS cell lines U2OS, Saos-2, HOS, and MG-63(ATCC, Manassas, VA, USA, CRL-11372™/RRID:CVCL_3708; HTB-96™/; HTB-85™/; CRL-1543™/; CRL-1427™/;) | |
| Primary cultures: Provide species, strain, sex of origin, genetic modification status. | n/a | |

| Experimental animals | Yes (indicate where provided: section/paragraph) | n/a |
|----------------------|-------------------------------------------------|-----|
| Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | n/a | |
| Animal observed in or captured from the field: Provide species, sex and age where possible | n/a | |
| Model organisms: Provide Accession number in repository (where relevant) OR RRID | n/a | |

| Plants and microbes | Yes (indicate where provided: section/paragraph) | n/a |
|---------------------|-------------------------------------------------|-----|
| Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | n/a | |
| Microbes: provide species and strain, unique accession number if available, and source | n/a | |

| Human research participants | Yes (indicate where provided: section/paragraph) | n/a |
|-----------------------------|-------------------------------------------------|-----|
| Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | All the experimental procedures were carried out according to the Helsinki declaration and approval was obtained from the Institutional Review Board of PLA | |
| Provide statement confirming informed consent obtained from study participants. | Before the beginning of the study, each patient signed written informed consent. | |
| Report on age and sex for all study participants. | The age and sex were not the most important element, then not make statistic. | |
### Design

| Study protocol | Yes (indicate where provided: section/paragraph) | n/a |
|----------------|-------------------------------------------------|-----|
| For clinical trials, provide the trial registration number OR cite DOI in manuscript. | – | n/a |

| Laboratory protocol | Yes (indicate where provided: section/paragraph) | n/a |
|---------------------|-------------------------------------------------|-----|
| Provide DOI or other citation details if detailed step-by-step protocols are available. | | n/a |

| Experimental study design (statistics details) | Yes (indicate where provided: section/paragraph) | n/a |
|------------------------------------------------|-------------------------------------------------|-----|
| State whether and how the following have been done, or if they were not carried out. | | n/a |
| Sample size determination | | n/a |
| Randomisation | | n/a |
| Blinding | | n/a |
| Inclusion/exclusion criteria | | n/a |

| Sample definition and in-laboratory replication | Yes (indicate where provided: section/paragraph) | n/a |
|-------------------------------------------------|-------------------------------------------------|-----|
| State number of times the experiment was replicated in laboratory | Every experiment repeat three times | |
| Define whether data describe technical or biological replicates | According to experiment introduction, technical replicates. | |

| Ethics | Yes (indicate where provided: section/paragraph) | n/a |
|--------|-------------------------------------------------|-----|
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | All the experimental procedures were carried out according to the Helsinki declaration and approval was obtained from the Institutional Review Board of PLA General Hospital. | |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | | n/a |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | All the experimental procedures were carried out according to the Helsinki declaration and approval was obtained from the Institutional Review Board of PLA General Hospital. Before the beginning of the study, each patient signed written informed consent. | |

| Dual Use Research of Concern (DURC) | Yes (indicate where provided: section/paragraph) | n/a |
|------------------------------------|-------------------------------------------------|-----|
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval | | n/a |
### Analysis

| Attribute        | Yes (indicate where provided: section/paragraph) | n/a |
|------------------|-------------------------------------------------|-----|
| Attrition        | No sample was excluded.                         |     |
| Statistics       | SPSS 22.0 (IBM, Chicago, USA) and GraphPad Prism 7 were used for statistical analysis. Statistical significance was analyzed by ANOVA. The Pearson correlation coefficient was used to evaluate the correlations. Data were expressed as the mean±SD. Group variations were regarded as statistically significant when P<0.05 between groups. |     |
| Data Availability| GSE140256: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140256  
GSE65071: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65071  
GSE87624: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87624 | n/a |
| Code Availability| For all newly generated code and software essential for replicating the main findings of the study: n/a |     |
| Reporting        | ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication. |     |

### Reporting

#### Adherence to community standards

MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.

State if relevant guidelines (e.g., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (e.g., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.

ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.
